Predictive value of FDG-PET in patients with advanced medullary thyroid cancer undergoing vandetanib treatment

被引：0
|
作者：
Werner, Rudolf [2 ,6 ]
Higuchi, Takahiro [4 ]
Muegge, Dirk [4 ]
Javadi, Mehrbod [3 ]
Fassnacht, Martin [5 ]
Buck, Andreas [4 ]
Lapa, Constantin [4 ]
Kreissl, Michael [1 ]
机构：
[1] Hosp Augsburg, Dept Nucl Med, Augsburg, Germany
[2] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Div Nucl Med, 600 N Wolfe St, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA
[4] Univ Hosp Wuerzburg, Dept Nucl Med, Wurzburg, Germany
[5] Univ Hosp WArzburg, Div Endocrinol & Diabet, Dept Internal Med 1, Wurzburg, Germany
[6] Univ Hosp WArzburg, Else KrAner Forschungskolleg, Dept Nucl Med, Wurzburg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
169
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Value of FDG-PET as a marker of treatment response
    Weber, W.
    EJC SUPPLEMENTS, 2007, 5 (08): : 8 - 8
  • [42] Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas
    Chougnet, Cecile N.
    Schlumberger, Martin
    Leboulleux, Sophie
    Baudin, Eric
    BULLETIN DU CANCER, 2014, 101 (09) : 891 - 895
  • [43] Value of 18-FDG PET/CT in medullary thyroid cancer patients with rapid calcitonin doubling times
    Patel, Niraj
    Kobayashi, Katsuhiro
    Tamara, Luis
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [44] The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature
    Stokkel, MPM
    Duchateau, CSJ
    Dragoiescu, C
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 50 (01): : 78 - 87
  • [45] Limited value of [18F]FDG-PET in localizing of recurrent/metastatic medullary thyroid carcinoma (MTC)
    Kurtaran, A
    Becherer, A
    Pötzí, C
    Scheuba, C
    Schmaljohann, J
    Kroiss, A
    Vierhapper, H
    Dudczak, R
    Niederle, B
    Kletter, K
    Virgolini, I
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 308P - 308P
  • [46] Predictive value of FDG-PET in rectal cancer: correlation with tumour characteristics and response.
    Turri, L.
    Apicella, F.
    Caroli, A.
    Grasso, R.
    Torrente, S.
    Puta, E.
    Ferrante, D.
    Sacchetti, G. M.
    Brambilla, M.
    Krengli, M.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S614 - S614
  • [47] Incidental thyroid cancer detected by FDG-PET/CT
    Ayan, Asli
    Gunalp, Bengul
    Okuyucu, Kursat
    Alagoz, Engin
    Emer, Mustafa
    Ince, Semra
    Arslan, Nuri
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [48] Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner
    Bockisch, A
    Brandt-Mainz, K
    Görges, R
    Müller, S
    Stattaus, J
    Antoch, G
    ACTA MEDICA AUSTRIACA, 2003, 30 (01) : 22 - 25
  • [49] TREATMENT WITH VANDETANIB IN A 11 YEARS OLD BOY WITH ADVANCED MEDULLARY THYROID CARCINOMA
    Papendieck, Patricia
    Vieites, Ana
    Elias, Eugenia
    Garcia Lombardi, Mercedes
    Chiesa, Ana
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 596 - 596
  • [50] Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort
    Chougnet, Cecile N.
    Borget, Isabelle
    Leboulleux, Sophie
    de la Fouchardiere, Christelle
    Bonichon, Francoise
    Criniere, Lise
    Niccoli, Patricia
    Bardet, Stephane
    Schneegans, Olivier
    Zanetta, Sylvie
    Schvartz, Claire
    Drui, Delphine
    Chauffert, Bruno
    Rohmer, Vincent
    Schlumberger, Martin
    THYROID, 2015, 25 (04) : 386 - 391
12345